Pliant pauses phase 2 lung fibrosis trial on advice of safety committee
Pliant Therapeutics has hit the breaks on a mid-stage trial of its lead liver disease drug on the advice of its safety committee.
Pliant Therapeutics has hit the breaks on a mid-stage trial of its lead liver disease drug on the advice of its safety committee.
